Autolus Therapeutics plc (AUTL) |
|
2.41 0.09 (3.88%)
|
09-28 16:00 |
|
Open: |
2.395 |
Pre. Close: |
2.32 |
|
High:
|
2.4144 |
Low:
|
2.29 |
|
Volume:
|
186,213 |
Market Cap:
|
419(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:49:03 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 3.45 One year: 3.98 |
| Support: |
Support1: 2.23 Support2: 1.85 |
| Resistance: |
Resistance1: 2.96 Resistance2: 3.41 |
| Pivot: |
2.7  |
| Moving Average: |
MA(5): 2.35 MA(20): 2.81
MA(100): 2.8 MA(250): 2.42 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 13.2 %D(3): 11.5 |
| RSI: |
RSI(14): 31.9 |
| 52-week: |
High: 3.53 Low: 1.6 |
| Average Vol(K): |
3-Month: 403 (K) 10-Days: 302 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AUTL ] has closed above bottom band by 22.3%. Bollinger Bands are 32.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.42 - 2.43 |
2.43 - 2.44 |
|
Low:
|
2.26 - 2.27 |
2.27 - 2.29 |
|
Close:
|
2.38 - 2.41 |
2.41 - 2.43 |
|
Company Description |
|
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. |
Headline News |
Sun, 17 Sep 2023
Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Update - MarketBeat
Tue, 05 Sep 2023
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood - Yahoo Finance
Mon, 07 Aug 2023
Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2023 Earnings Call Transcript - Yahoo Finance
Wed, 19 Jul 2023
Autolus Therapeutics announces appointment of Robert F. Dolski as ... - GlobeNewswire
Fri, 16 Jun 2023
Autolus Therapeutics Presents Positive Results from AUTO4 in ... - GlobeNewswire
Fri, 02 Jun 2023
Is Autolus Therapeutics PLC (AUTL) a Good Choice in Biotechnology Friday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
174 (M) |
|
% Held by Insiders
|
5.622e+007 (%) |
|
% Held by Institutions
|
8.4 (%) |
|
Shares Short
|
1,870 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.5968e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
223.6 |
|
Return on Equity (ttm)
|
-27.3 |
|
Qtrly Rev. Growth
|
7.49e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-47.22 |
|
EBITDA (p.s.)
|
-8.84189e+007 |
|
Qtrly Earnings Growth
|
-1.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-127 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.06 |
|
Price to Cash Flow
|
2.7 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.37e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
